As an EGFR inhibitor, the MD experiments showed that the binding of compound SMUZ106 to EGFR was stable and specific, and we investigated the ability of SMUZ106 to inhibit EGFR auto-phosphorylation activity in the GBM cells. The gene discussed is EGFR; the disease is glioblastoma.